

MAY. 9. 2008 6:28PM ENZO BIOCHEM

RECEIVED  
CENTRAL FAX CENTER

NO. 5384 P. 4

**MAY 09 2008**

Dakai Liu and Elazar Rabbani

Serial No. 09/046,833

Filed: March 24, 1998

Page 3 [Amendment Under 37 C.F.R. §1.165 (In Reply To The  
April 29, 2008 Office Communication) – May 9, 2008]

**Listing of Claims:**

Claims 1-90 (Canceled).

91. (Currently Amended) A packaging cell line for propagating a viral vector independent of a helper virus, said viral vector comprising a nucleic acid component and at least two different non-nucleic components, wherein one of said non-nucleic acid components has a tropism for said cell line and the other non-nucleic acid component has a tropism for a target cell which is different from said cell line, said nucleic acid component and said non-nucleic acid components being capable of forming a specific complex or complexes, wherein said sequence or sequences for the viral vector nucleic acid component have been stably integrated in the genome of said cell line, and sequences for the non-nucleic acid components of said viral vector have been stably integrated in the genome of said cell line and code for envelope genes proteins from two different viruses.

92. (Previously Presented) The packaging cell line of claim 91, wherein said viral vector comprises a retrovirus or retroviral sequences.

93. (Previously Presented) The packaging cell line of claim 91, wherein said viral vector nucleic acid component comprises nucleic acid sequences derived from genomic DNA, cDNA, or fragments of either or both of the foregoing.

94. (Previously Presented) The packaging cell line of claim 91, wherein said packaging cell line and said target cell are from different species.

95. (Previously Presented) The packaging cell line of claim 94, wherein said packaging cell line is a non-human animal species and said target cell is human.

**Enz-56(D4)**

Dakai Liu and Elazar Rabbani  
Serial No. 09/046,833  
Filed: March 24, 1998  
Page 4 [Amendment Under 37 C.F.R. §1.165 (In Reply To The  
April 29, 2008 Office Communication) – May 9, 2008]

96. (Previously Presented) The packaging cell line of claim 95, wherein said non-human animal species is murine.
97. (Previously Presented) The packaging cell line of claim 91, wherein said target cell comprises T cells, liver cells, bone marrow cells, epithelial cells, or a combination of any of the foregoing.
98. (Previously Presented) The packaging cell line of claim 91, wherein the viral vector produced from said packaging cell line codes for a protein of interest that is expressed in said target cell.
99. (Previously Presented) The packaging cell line of claim 91, wherein the viral vector produced from said packaging cell line codes for an antisense RNA that is transcribed in said target cell.
100. (Previously Presented) The packaging cell line of claim 91, wherein the viral vector produced from said packaging cell line codes for a protein of interest that is expressed in said target cell and for an antisense RNA that is transcribed in said target cell.
101. (Previously Presented) The packaging cell line of claim 99, wherein said antisense RNA is complementary to an mRNA coding for a undesirable protein in said target cell.
102. (Previously Presented) The packaging cell line of claim 100, wherein said antisense RNA is complementary to an mRNA coding for a undesirable protein in said target cell.

Enz-56(D4)

Dakai Liu and Elazar Rabbani

Serial No. 09/046,833

Filed: March 24, 1998

Page 5 [Amendment Under 37 C.F.R. §1.165 (In Reply To The April 29, 2008 Office Communication) – May 9, 2008]

103. (Previously Presented) The packaging cell line of claim 99, wherein said antisense RNA is part of a chimeric RNA molecule that comprises sequences from small nuclear RNAs (snRNAs).

104. (Previously Presented) The packaging cell line of claim 100, wherein said antisense RNA is part of a chimeric RNA molecule that comprises sequences from small nuclear RNAs (snRNAs).

105. (Currently Amended) The packaging cell line of claim 99, wherein said antisense RNA is either (i) complementary to an mRNA coding for a undesirable protein in said target cell or (ii) is part of a chimeric RNA molecule that comprises sequences from small nuclear RNAs (snRNAs).

106. (Previously Presented) The packaging cell line of claim 103, wherein said snRNAs comprises U1, U2, U3, U4, U5, U6, U7, U8, U9, U10 or U11.

107. (Previously Presented) The packaging cell line of claim 104, wherein said snRNAs comprises U1, U2, U3, U4, U5, U6, U7, U8, U9, U10 or U11.

108. (Previously Presented) The packaging cell line of claim 105, wherein said snRNAs comprises U1, U2, U3, U4, U5, U6, U7, U8, U9, U10 or U11.

109. (Previously Presented) The packaging cell line of claim 91, wherein said nucleic acid component comprises sequences derived from a virus that has a tropism to said cell line.

110. (Previously Presented) The packaging cell line of claim 91, wherein said nucleic acid component comprises sequences derived from a virus that has a tropism to said target cell.

Enz-56(D4)

Dakai Liu and Elazar Rabbani  
Serial No. 09/046,833  
Filed: March 24, 1998  
Page 6 [Amendment Under 37 C.F.R. §1.165 (In Reply To The  
April 29, 2008 Office Communication) – May 9, 2008]

111. (Previously Presented) The packaging cell line of claim 91, wherein said nucleic acid component comprises sequences derived from a virus that has a tropism to said cell line and sequences derived from a different virus that has a tropism to said target cell.

112. (Currently Amended) A packaging cell line for propagating a viral vector independent of a helper virus, said viral vector comprising a nucleic acid component and at least two different non-nucleic acid components, wherein one of said non-nucleic acid components has a tropism for said cell line and the other non-nucleic acid component has a tropism for a target cell which is different from said cell line, said nucleic acid component and said non-nucleic acid components being capable of forming a specific complex or complexes, and wherein sequences for the non-nucleic acid components of said viral vector have been stably integrated in the genome of said cell line and code for envelope genes proteins from two different viruses.

113. (Previously Presented) The packaging cell line of claim 112, wherein said viral vector comprises a retrovirus or retroviral sequences.

114. (Previously Presented) The packaging cell line of claim 112, wherein said packaging cell line and said target cell are from different species.

115. (Previously Presented) The packaging cell line of claim 112, wherein said packaging cell line is a non-human animal species and said target cell is human.

116. (Previously Presented) The packaging cell line of claim 115, wherein said non-human animal species is murine.

Enz-56(D4)

Dakai Liu and Elazar Rabbani

Serial No. 09/046,833

Filed: March 24, 1998

Page 7 [Amendment Under 37 C.F.R. §1.165 (In Reply To The  
April 29, 2008 Office Communication) – May 9, 2008]

117. (Previously Presented) The packaging cell line of claim 112, wherein said target cell comprises T cells, liver cells, bone marrow cells, epithelial cells, or a combination of any of the foregoing.

\* \* \* \* \*

Enz-56(D4)